IN2014MN02214A - - Google Patents

Info

Publication number
IN2014MN02214A
IN2014MN02214A IN2214MUN2014A IN2014MN02214A IN 2014MN02214 A IN2014MN02214 A IN 2014MN02214A IN 2214MUN2014 A IN2214MUN2014 A IN 2214MUN2014A IN 2014MN02214 A IN2014MN02214 A IN 2014MN02214A
Authority
IN
India
Prior art keywords
formulations
incision
infiltration
administered
injection
Prior art date
Application number
Other languages
English (en)
Inventor
Shimon Amselem
Michael Naveh
Original Assignee
Painreform Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Painreform Ltd filed Critical Painreform Ltd
Publication of IN2014MN02214A publication Critical patent/IN2014MN02214A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2214MUN2014 2012-05-10 2013-05-09 IN2014MN02214A (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261645066P 2012-05-10 2012-05-10
US201261649400P 2012-05-21 2012-05-21
US201361781595P 2013-03-14 2013-03-14
US201361781625P 2013-03-14 2013-03-14
PCT/IL2013/050410 WO2013168172A1 (en) 2012-05-10 2013-05-09 Depot formulations of a local anesthetic and methods for preparation thereof

Publications (1)

Publication Number Publication Date
IN2014MN02214A true IN2014MN02214A (de) 2015-07-17

Family

ID=49550270

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2213MUN2014 IN2014MN02213A (de) 2012-05-10 2013-05-09
IN2214MUN2014 IN2014MN02214A (de) 2012-05-10 2013-05-09

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN2213MUN2014 IN2014MN02213A (de) 2012-05-10 2013-05-09

Country Status (9)

Country Link
US (3) US9849088B2 (de)
EP (2) EP2846772A4 (de)
JP (4) JP2015516411A (de)
CN (2) CN104427976B (de)
AU (2) AU2013257546B2 (de)
CA (2) CA2871820C (de)
IN (2) IN2014MN02213A (de)
RU (2) RU2678433C2 (de)
WO (2) WO2013168167A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013168167A1 (en) * 2012-05-10 2013-11-14 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
WO2017009861A1 (en) * 2015-07-13 2017-01-19 Neon Laboratories Limited Hyperbaric injection solution of ropivacaine hydrochloride and process for preparation thereof
CA3078555A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
WO2019226599A1 (en) * 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用
JP7378929B2 (ja) * 2018-12-27 2023-11-14 花王株式会社 リポソームの製造方法
CN111388418B (zh) * 2018-12-31 2022-09-06 北京泰德制药股份有限公司 一种含有罗哌卡因或其药用盐的药物组合物
EP3991722A4 (de) * 2019-06-28 2022-10-05 Jiangsu Hengrui Medicine Co., Ltd. Lipidzusammensetzung mit verzögerter wirkstoffabgabe und ihr herstellungsverfahren
EP4091612A4 (de) * 2020-01-14 2024-01-24 Shanghai Inst Materia Medica Cas Langwirkende pharmazeutische ropivacain-zusammensetzung, verfahren zu ihrer herstellung und ihre verwendung
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
CN115463084B (zh) * 2021-06-10 2024-05-28 北京泰德制药股份有限公司 一种长效镇痛用复方油溶液制剂及其制备方法
CN117999070A (zh) * 2021-09-15 2024-05-07 美国奥科视光有限公司 用于治疗干燥皮肤的软膏
WO2024050176A1 (en) * 2022-08-27 2024-03-07 Rubin Darren Alexander Injectable methods to treat deficiencies in glutathione metabolism and homocystinuria

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252793A (en) 1979-06-18 1981-02-24 American Lecithin Company Injectable lecithin preparation
WO1995013796A1 (en) 1993-11-16 1995-05-26 Depotech Corporation Vesicles with controlled release of actives
JPH0753661B2 (ja) 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
US5173219A (en) 1986-02-12 1992-12-22 Research Development Foundation Uniform spherical multilamellar liposomes of defined and adjustable size distribution
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
NZ223660A (en) 1987-03-05 1990-11-27 Liposome Co Inc Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity
CH681427A5 (de) 1987-07-01 1993-03-31 Zambon Spa
US5807572A (en) 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5576017A (en) 1988-05-30 1996-11-19 Depotech Corporation Heterovesicular liposomes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
EP0643620B1 (de) * 1991-10-04 1999-07-21 Gs Development Ab Teilchen, methode zur herstellung der teilchen und deren verwendung
SE9200952D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
ATE195652T1 (de) 1992-12-02 2000-09-15 Alkermes Inc Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
SE9302218D0 (sv) * 1993-06-28 1993-06-28 Ab Astra New use
CA2166465C (en) * 1993-07-08 2003-10-14 Laura M. Edgerly-Pflug Method of controlling the size of liposomes
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US5635206A (en) * 1994-01-20 1997-06-03 Hoffmann-La Roche Inc. Process for liposomes or proliposomes
CA2153553A1 (en) 1994-07-13 1996-01-14 Hidekazu Suzuki Stable lipid emulsion
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
HU223475B1 (hu) * 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5981592A (en) 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2230448A1 (en) 1995-08-28 1997-03-06 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
ATE183092T1 (de) * 1995-10-28 1999-08-15 Braun Melsungen Ag Lokalanästhetika und/oder zentralanalgetika enthaltende pharmazeutische zusammensetzungen
US5744337A (en) * 1995-12-26 1998-04-28 The United States Of America As Represented By The Secretary Of The Navy Internal gelation method for forming multilayer microspheres and product thereof
FR2753626B1 (fr) 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US6306432B1 (en) 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
JP4467789B2 (ja) * 1997-09-18 2010-05-26 パシラ ファーマシューティカルズ インコーポレーテッド 持続放出性リポソーム麻酔組成物
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
EP0996461B1 (de) 1997-10-31 2005-01-12 Walter Reed Army Institute of Research Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
CA2309548A1 (en) 1997-11-14 1999-05-27 Skyepharma Inc. Production of multivesicular liposomes
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6277413B1 (en) 1998-07-17 2001-08-21 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
ATE262916T1 (de) * 1998-08-18 2004-04-15 Panacea Biotec Ltd Zusammensetzung enthalten cyclsoporin in einem hydrophilen träger
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
EP1189597A4 (de) 1999-06-04 2008-06-18 Pacira Pharmaceuticals Inc Zusammensetzungen mit einem öl-kern zur verzögerten freisetzung hydrophober arzneistoffe
KR100343125B1 (ko) 1999-09-14 2002-07-05 임정옥 도포용 리포좀형 혼합국소마취제 및 그 제조방법
EP1138313A1 (de) * 2000-03-28 2001-10-04 Primacare S.A. Pro-liposomen
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
IL139177A0 (en) 2000-10-20 2001-11-25 S C Republic Dev S R L Sustained release drug delivery system
AU2002322024B2 (en) 2001-05-31 2008-05-08 Pacira Pharmaceuticals, Inc. Encapsulation of nanosuspensions in liposomes and microspheres
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
WO2003047595A1 (en) 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds
AU2003226285B2 (en) 2002-04-10 2008-01-03 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US7229630B2 (en) 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US20030236306A1 (en) 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
AU2003266159A1 (en) * 2002-09-16 2004-04-30 Zicam, Llc. System and method for delivering a composition to the nasal membrane
CA2501239A1 (en) 2002-10-07 2004-04-22 Encore Pharmaceuticals, Inc. R-nsaid esters and their use
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050049209A1 (en) 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7968122B2 (en) 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US20050186230A1 (en) 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
WO2005082382A1 (en) 2004-02-23 2005-09-09 Attenuon Llc Formulations of thiomolybdate or thiotungstate compounds and uses thereof
ES2309766T3 (es) 2004-06-04 2008-12-16 Camurus Ab Formulaciones liquidas de liberacion lenta.
JP2008502690A (ja) * 2004-06-15 2008-01-31 アンドリュー シァン チェン， リン脂質組成物ならびにその調製方法および使用方法
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
EP1778217A4 (de) 2004-07-28 2008-10-08 Sd Pharmaceuticals Inc Stabile injizierbare zusammensetzung von alpha-tocopherylsuccinat; analoga und salze davon"
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
KR20080039400A (ko) 2005-07-07 2008-05-07 파남 컴퍼니스 인크. 고수용성 약물의 서방성 약학 조성물
US20070078434A1 (en) * 2005-09-30 2007-04-05 Vyteris, Inc. Indications For Local Transport of Anaesthetic Agents By Electrotransport Devices
CA2631755A1 (en) 2005-12-02 2007-06-07 Adventrx Pharmaceuticals, Inc. Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
CN100518738C (zh) 2006-01-06 2009-07-29 中国药科大学 一种含喜树碱类药物的自组装前体脂质体及其制备方法
CN100563715C (zh) 2006-01-06 2009-12-02 中国药科大学 一种紫杉醇自组装前体脂质体及其制备方法
CN100486569C (zh) 2006-01-06 2009-05-13 中国药科大学 一种多烯紫杉醇自组装前体脂质体及其制备方法
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2008127456A2 (en) * 2006-12-07 2008-10-23 Lyotropic Therapeutics, Inc. Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
EP1938801A1 (de) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US20100041704A1 (en) * 2007-01-12 2010-02-18 Aberg A K Gunnar Dermal compositions of substituted amides and the use thereof as medication for pain and pruritus
ATE476176T1 (de) 2007-03-02 2010-08-15 Farnam Co Inc Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
CA2681302C (en) * 2007-03-19 2013-07-23 Dhiraj Khattar Proliposomal and liposomal compositions of poorly water-soluble compounds
BRPI0704542B8 (pt) 2007-05-15 2021-05-25 Univ Estadual Campinas Unicamp composição farmacêutica, processo de obtenção da composição farmacêutica, uso de uma quantidade farmaceuticamente eficaz de anestésico e agente gelificante, produto e método de tratamento
RU2429242C2 (ru) * 2007-05-30 2011-09-20 Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) Применение тетранитрозильного комплекса железа с тиофенолом в качестве противоопухолевого лекарственного средства
HUP0700426A2 (en) 2007-06-19 2010-03-29 Invencio 21 Gyogyhatasu Keszit Liposomal compound
EP2178893A4 (de) 2007-07-16 2012-09-19 Poniard Pharmaceuticals Inc Orale formulierungen für picoplatin
FR2924024B1 (fr) 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
CN101485629B (zh) 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
CN102202654B (zh) 2008-09-04 2014-07-30 法纳姆公司 可咀嚼的缓释制剂
US9248098B2 (en) 2008-10-10 2016-02-02 Dara Biosciences, Inc. Treating or preventing pain using spicamycin derivatives
WO2010138918A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
WO2011031462A2 (en) 2009-08-25 2011-03-17 Latitude Pharmaceuticals Incorporated Compositions for delivery of insoluble agents
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
EP2336286A1 (de) * 2009-12-18 2011-06-22 The Procter & Gamble Company Zusammensetzung mit Mikrokapseln
US8313766B2 (en) 2010-02-05 2012-11-20 Andrew Chen Oral antidepressant formulation with reduced excipient load
US20140066481A1 (en) 2010-04-01 2014-03-06 Pharmanest Ab Water-Free Pharmaceutical Compositions Suitable for Local Anaesthetics
US20110250264A1 (en) 2010-04-09 2011-10-13 Pacira Pharmaceuticals, Inc. Method for formulating large diameter synthetic membrane vesicles
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
WO2011153513A2 (en) 2010-06-03 2011-12-08 Latitude Pharma Nanoemulsion composition containing vitamin k
EP2588081A4 (de) 2010-06-29 2014-12-10 Verastem Inc Orale formulierung aus kinasehemmern
CN103052382B (zh) 2010-07-14 2014-10-22 千寿制药株式会社 α-酮酰胺衍生物的固体分散体
AU2010359346B2 (en) 2010-08-20 2015-01-29 Dr. Reddy's Laboratories Sa Phospholipid depot
WO2012037311A1 (en) 2010-09-17 2012-03-22 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
WO2012054447A2 (en) 2010-10-22 2012-04-26 Dr. Reddy's Laboratories, Inc. Use of storage stable viscous phospholipid depot to treat wounds
JP6194248B2 (ja) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
WO2012170796A1 (en) 2011-06-09 2012-12-13 Amylin Pharmaceuticals, Inc. Gel compositions
WO2013168167A1 (en) * 2012-05-10 2013-11-14 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof

Also Published As

Publication number Publication date
WO2013168172A1 (en) 2013-11-14
AU2013257546B2 (en) 2017-12-14
CA2871820C (en) 2020-11-03
JP2018035179A (ja) 2018-03-08
JP2017222729A (ja) 2017-12-21
JP6574228B2 (ja) 2019-09-11
AU2013257546A1 (en) 2014-11-27
AU2013257608A1 (en) 2014-11-27
CA2871821C (en) 2021-01-12
EP2846772A4 (de) 2015-12-30
AU2013257608B2 (en) 2017-12-14
US9668974B2 (en) 2017-06-06
RU2678433C2 (ru) 2019-01-29
CN104427977A (zh) 2015-03-18
CN104427977B (zh) 2018-02-02
IN2014MN02213A (de) 2015-07-10
RU2014144501A (ru) 2016-07-10
US20150148325A1 (en) 2015-05-28
JP2015516411A (ja) 2015-06-11
CN104427976A (zh) 2015-03-18
EP2846773A4 (de) 2015-12-30
JP2015516412A (ja) 2015-06-11
US20180049985A1 (en) 2018-02-22
US9849088B2 (en) 2017-12-26
EP2846772A1 (de) 2015-03-18
RU2014144500A (ru) 2016-07-10
CA2871821A1 (en) 2013-11-14
US20150111923A1 (en) 2015-04-23
CN104427976B (zh) 2018-04-24
RU2664700C2 (ru) 2018-08-21
WO2013168167A1 (en) 2013-11-14
US10206876B2 (en) 2019-02-19
EP2846773A1 (de) 2015-03-18
CA2871820A1 (en) 2013-11-14
JP6577548B2 (ja) 2019-09-18

Similar Documents

Publication Publication Date Title
IN2014MN02214A (de)
PH12019500176A1 (en) Heterocyclic compounds and ther uses
HK1203840A1 (en) Pharmaceutical composition and administration thereof
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
MX2020002693A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
EP2998307A4 (de) Phosphorsäure-/phosphonsäurederivate und medizinische verwendungen davon
SG10201804817TA (en) Delayed release compositions of linaclotide
EP3143997A3 (de) Verfahren zur verabreichung einer pirfenidontherapie
IN2014DN10670A (de)
MX2016005395A (es) Formulacion estable de insulina glulisina.
MX2015012416A (es) Compuestos heterociclicos y sus usos.
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
EP3162804A8 (de) Neues benzodiazepinderivat und verwendung davon
IN2014MN02236A (de)
HK1221152A1 (zh) 用於呋塞米的皮下施用的藥物製劑
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
EP3020417A4 (de) Pharmazeutische zusammensetzung zur respiratorischen verabreichung
PH12016501117A1 (en) Pharmaceutical compositions of carotenoid
IL236562A0 (en) A pharmaceutical preparation with an improved flow capacity, a medical agent, and a method for its production and use
BR112015025781A2 (pt) composição farmacêutica para uso inalatório e kit para a administração de um fármaco como um pó inalatório
IN2012DE00826A (de)
EP2668952A3 (de) Wässrige Formulierungen aus Bisphosphonaten, Vitamin D und Benzylalkohol, die zur subkutanen oder intramuskulären Verwendung geeignet sind
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
ZA201303220B (en) Stable pharmaceutical composition of a benzimidazole proton pump inhibitor and method for the preparation thereof
UA73592U (ru) Применение экстракта травы герани крупнокорневищной как средства с противовоспалительной и обезболивающей активностью